39 unchanged sentences
There were no changes in our internal control over financial reporting for the quarter ended December 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
−Removed: We are continually monitoring and assessing the status of the COVID-19 pandemic to determine any potential impact on the design and operating effectiveness of our internal controls over financial reporting.
+Added: We are continually monitoring and assessing the pandemic status and geopolitical environment to determine any potential impact on the design and operating effectiveness of our internal controls over financial reporting.
Other Information
−Removed: JHS Manufacturing and Supply Agreement
−Removed: On February 23, 2022, our wholly-owned subsidiary, LMI, entered into a Manufacturing and Supply Agreement (the “MSA”) with JHS, effective as of February 23, 2022, pursuant to which JHS will manufacture, and LMI will purchase, our DEFINITY, NEUROLITE, Cardiolite and evacuation vial products.
−Removed: The new MSA supersedes all of the prior agreements of the parties.
−Removed: The initial term of the MSA runs through December 31, 2027 and can be further extended by mutual agreement of the parties.
−Removed: The MSA requires LMI to purchase from JHS specified percentages of its total requirements for DEFINITY, as well as specified quantities of NEUROLITE, Cardiolite and evacuation vial products, each year during the contract term.
−Removed: Either party can terminate the MSA upon the occurrence of certain events, including, but not limited to, the material breach or bankruptcy of the other party.
+Added: Not Applicable
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
32 unchanged sentences
Number Description of Exhibits Form File Number Exhibit Filing Date
−Removed: 2.1 Agreement and Plan of Merger, dated as of October 1, 2019, among Lantheus Holdings, Inc., Plato Merger Sub, Inc.
−Removed: and Progenics Pharmaceuticals, Inc.
−Removed: 8-K 001-36569 10.1 October 2, 2019
3.1 Amended and Restated Certificate of Incorporation of Lantheus Holdings, Inc.
5 unchanged sentences
4.2* Description of Registrant’s Securities
+Added: 4.3 Indenture, dated as of December 8, 2022, between Lantheus Holdings, Inc., as Issuer, Lantheus Medical Imaging, Inc., as Guarantor, and U.S.
+Added: Bank Trust Com pany, National Association, as Trustee
+Added: 8-K 001-36569 4.1 December 8, 2022
10.1+ Lantheus Holdings, Inc.
11 unchanged sentences
S-4 333-169785 10.21 October 6, 2010
−Removed: 10.9† Manufacturing and Supply Agreement, dated as of February 1, 2012, for the manufacture of DEFINITY® by and between Lantheus Medical Imaging, Inc.
−Removed: and Jubilant HollisterStier LLC.
−Removed: 10-Q 333-169785 10.2 May 15, 2012
−Removed: 10.10† First Amendment to Manufacturing and Supply Agreement, dated as of May 3, 2012, for the manufacture of DEFINITY® by and between Lantheus Medical Imaging, Inc.
−Removed: and Jubilant HollisterStier LLC.
−Removed: 10-Q 333-169785 10.1 August 14, 2012
10.5+ Lantheus Holdings, Inc.
20 unchanged sentences
8-K 001-36569 10.1 April 28, 2016
−Removed: 10.21† Second Amendment, effective September 2, 2016, to the Manufacturing and Supply Agreement, dated as of February 1, 2012 and amended on May 3, 2012, by and between Lantheus Medical Imaging, Inc.
−Removed: and Jubilant HollisterStier LLC.
−Removed: 10-Q 001-36569 10.2 November 1, 2016
−Removed: Incorporated by Reference
−Removed: Number Description of Exhibits Form File Number Exhibit Filing Date
10.14+ Second Amendment to Lantheus Holdings, Inc.
10 unchanged sentences
10-K 001-36569 10.68 February 20, 2019
−Removed: 10.26+ Employment Agreement dated as of November 22, 2013, by and between Lantheus Medical Imaging, Inc.
−Removed: and Michael Duffy.
−Removed: 10-K 001-36569 10.69 February 20, 2019
10.18+ Form of Severance Agreement (executives with existing employment agreements).
5 unchanged sentences
10-Q 001-36569 10.1 April 30, 2019
+Added: Incorporated by Reference
+Added: Number Description of Exhibits Form File Number Exhibit Filing Date
10.21+ Fourth Amendment to Lantheus Holdings, Inc.
1 unchanged sentence
10-Q 001-36569 10.2 July 25, 2019
−Removed: 10.31 Credit Agreement dated as of June 27, 2019 by and among Wells Fargo Bank, N.A., as administrative agent and collateral agent, each of the lenders from time to time party thereto, Lantheus Medical Imaging, Inc., as borrower, and Lantheus Holdings, Inc.
−Removed: 10-Q 001-36569 10.3 July 25, 2019
−Removed: 10.32 Amendment No.
−Removed: 1 to Credit Agreement, dated as of June 19, 2020, among Lantheus Medical Imaging, Inc., as borrower, Lantheus Holdings, Inc.
−Removed: and Wells Fargo Bank, N.A., as administrative agent and collateral agent*
−Removed: 10-Q 001-36539 10.2 July 31, 2020
10.22 Contingent Value Rights Agreement dated as of June 19, 2020, by and between Lantheus Holdings, Inc.
9 unchanged sentences
S-8 333-239491 4.5 June 26, 2020
−Removed: 10.36 License Agreement, dated February 3, 2011, by and between Salix Pharmaceuticals, Inc., the Registrant, Progenics Pharmaceuticals Nevada, Inc.
−Removed: and Excelsior Life Sciences Ireland Limited.
−Removed: 10-Q 000-23143 10.37(16) May 10, 2011
10.25 Lease, dated December 31, 2015, between the Registrant and WTC TOWER 1 LLC.
8-K 000-23143 10.46 (21) January 5, 2016
−Removed: 10.38+ Consulting Agreement by and between Lantheus Medical Imaging, Inc.
−Removed: and Michael P.
−Removed: Duffy, dated as of March 31, 2021
−Removed: 8-K 001-36569 10.1 April 1, 2021
10.26+ Fifth Amendment to Lantheus Holdings, Inc.
1 unchanged sentence
8-K 001-36569 10 April 29, 2021
+Added: 10.27†† Manufacturing and Supply Agreement, effective as of February 23, 2022, by and between Lantheus Medical Imaging, Inc.
+Added: and Jubilant HollisterStier LLC.
+Added: 10-Q 001-36569 10.1 April 29, 2022
+Added: 10.28 Form of Restricted Stock Unit Award Agreement (Employee Time-Based Vesting) of Lantheus Holdings, Inc.
+Added: 10-Q 001-36569 10.2 April 29, 2022
+Added: 10.29 Form of Restricted Stock Unit Award Agreement (Relative Total Shareholder Return Performance-Based Vesting) of Lantheus Holdings, Inc.
+Added: 10-Q 001-36569 10.3 April 29, 2022
+Added: 10.30 Form of Stock Option Award Agreement (Time Vesting) of Lantheus Holdings, Inc.
+Added: 10-Q 001-36569 10.4 April 29, 2022
+Added: 10.31 Sixth Amendment to Lantheus Holdings, Inc.
+Added: 2015 Equity Incentive Plan
+Added: 8-K 001-36569 10.1 May 2, 2022
+Added: 10.32†† License and Collaboration Agreement, dated as of November 11, 2022, by and between Point Biopharma, Inc., and Lantheus Two, LLC.
+Added: 8-K 000-36569 10.1 November 14, 2022
+Added: 10.33 Credit Agreement dated as of December 2, 2022 by and among Citizens Bank, N.A., as administrative agent and collateral agent, each of the lenders from time to time party thereto, Lantheus Medical Imaging, Inc., as borrower, and Lantheus Holdings, Inc.
+Added: 8-K 001-36569 10.1 December 5, 2022
21.1* Subsidiaries of Lantheus Holdings, Inc.
43 unchanged sentences
Brian Markison
+Added: /S/ MINNIE BAYLOR-HENRY Director February 23, 2023
+Added: Minnie Baylor-Henry
/S/ GÉRARD BER
8 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.